WHAT IS CLAIMED IS:

1. A composition for treating or preventing a corneoscleral disease, disorder or condition in a human or veterinary animal in need of treatment or prevention thereof, said composition comprising (a) at least one collagen mimetic peptide (CMP), and (b) one or more pharmaceutically suitable carriers.

2. The composition of claim 1, wherein said corneoscleral disease, disorder or condition is selected from the group consisting of keratitis, episcleritis, scleritis, corneal ulceration, sequelae of corneal ulceration, corneal ectasia, acquired abnormalities of corneal shape, keratoconus, corneal astigmatism, keratoglobus, posterior corneal depressions, keratectasia, keratocele, descemetocele, pellucid marginal degeneration, Terrien's marginal dystrophy, Mooren's ulcers, central corneal ulcers, marginal corneal ulcers, staph marginal ulceration, Salzman's nodular dystrophy, age-related peripheral corneal atrophy, geographic ulceration, disciform stromal keratitis, metaherpetic ulceration, keratomalacia, post penetrating keratoplasty, incisional wounds, anterior membrane dystrophies, stromal dystrophies, ocular mucous membrane pemphigoid, necrotizing scleritis, scleromalacia, coloboma, myopia, presbyopia, hyperopia, scleral buckle induced scleromalacia, congenital hereditary stromal dystrophy, congenital anterior staphyloma, sclerocornea, traumatic breaks in Descemet's membrane, corneal keloids, scleral ectasia, scleral staphyloma, deep scleritis, necrotizing scleritis, scleromalacia perforans, hyaline degeneration of the sclera, paralimbal scleromalacia, ocular graft vs host disease, and choroideremia.

3. The composition of claim 1 or claim 2, wherein said at least one CMP is attached to at least one therapeutic compound (TC) to form a CMP-TC conjugate.

4. The composition of any one of claims 1-3, wherein said at least one collagen mimetic peptide has an amino acid sequence corresponding to any one of SEQ ID NOs:1-388, 397-416, and 418-470.

5. Use of the composition of any one of claims 1-4 in a dosage sufficient to treat or prevent a corneoscleral disease, disorder or condition in the manufacture of a medicament for treating or preventing said corneoscleral disease, disorder or condition in a human or veterinary animal in need of treatment or prevention thereof.

6. The use of claim 5, wherein said corneoscleral disease, disorder or condition is selected from the group consisting of keratitis, episcleritis, scleritis, corneal ulceration, sequelae of corneal ulceration, corneal ectasia, acquired abnormalities of corneal shape, keratoconus, corneal astigmatism, keratoglobus, posterior corneal depressions, keratectasia, keratocele, descemetocele, pellucid marginal degeneration, Terrien's marginal dystrophy, Mooren's ulcers, central corneal ulcers, marginal corneal ulcers, staph marginal ulceration, Salzman's nodular dystrophy, age-related peripheral corneal atrophy, geographic ulceration, disciform stromal keratitis, metaherpetic ulceration, keratomalacia, post penetrating keratoplasty, incisional wounds, anterior membrane dystrophies, stromal dystrophies, ocular mucous membrane pemphigoid, necrotizing scleritis, scleromalacia, coloboma, myopia, presbyopia, hyperopia, scleral buckle induced scleromalacia, congenital hereditary stromal dystrophy, congenital anterior staphyloma, sclerocornea, traumatic breaks in Descemet's membrane, corneal keloids, scleral ectasia, scleral staphyloma, deep scleritis, necrotizing scleritis, scleromalacia perforans, hyaline degeneration of the sclera, paralimbal scleromalacia, ocular graft vs host disease, and choroideremia.

7. The use of claim 5 or claim 6, wherein said corneoscleral disease, disorder or condition is selected from the group consisting of myopia, keratoconus and presbyopia.

8. The use of any one of claims 5-7, wherein said corneoscleral disease, disorder or condition is myopia.

9. The use of any one of claims 5-7, wherein said corneoscleral disease, disorder or condition is presbyopia.

10. The use of any one of claims 5-9, wherein said composition is to be administered to the eye conjunctivally or subconjunctivally.

11. The use of any one of claims 5-9, wherein said composition is to be administered to the eye in the form of one or more drops of solution or a suspension that contains the composition.

12. The use of any one of claims 5-9, wherein said composition is to be administered to the eye via injection.

13. The use of claim 12, wherein said injection is intravitreal injection.

14. The use of any one of claims 5-9, wherein said composition is to be administered to the eye in the form of a coating on a solid material that is implanted into an eye structure.

15. The use of any one of claims 5-9, wherein said composition is to be administered to the eye in the form of a wafer, film, gel, mesh or patch.

16. The use of any one of claims 5-15, wherein said composition is attached to one or more spheres or nanoparticles that are to be delivered to or into an eye structure.

17. A medical device suitable for treating or preventing a corneoscleral disease, disorder or condition in a human or veterinary animal in need of treatment or prevention thereof, wherein said device comprises the composition of any one of claims 1-4.

18. The medical device of claim 17, wherein said device is selected from the group consisting of a stent, a shunt, a suture, an absorbable mesh, an absorbable patch, a drug-releasing wafer, a film, and an internal infusion pump.

19. Use of the medical device of claim 17 or claim 18 to treat, ameliorate or prevent myopia, keratoconus, or presbyopia in a human or veterinary animal in need of treatment or prevention thereof.